Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Long-term (52-week), Safety Trial of the Fixed Dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 12.5mg and Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg in Patients With Essential Hypertension - Efficacy and Safety Evaluation

NCT00326768 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00326768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00326768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Long-term (52-week), Safety Trial of the Fixed Dose Combination of Telmisartan 80mg Plus Hydrochlorothiazide 12.5mg and Telmisartan 40mg Plus Hydrochlorothiazide 12.5mg in Patients With Essential Hypertension - Efficacy and Safety Evaluation
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2006
Completion date
August 31, 2007
Enrollment
184 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension